|
AstraZeneca And Rigel Sign Worldwide License Agreement For A …
MarketWatch (press release) "R256 emerged from Rigel's comprehensive study of chronic and severe asthma and lung inflammation. With AstraZeneca as our development partner, severely … |
View full post on asthma – Google News